Fernández-Irigoyen Joaquín, Corrales Fernando, Santamaría Enrique
Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, Proteored-ISCIII, Pamplona, Spain.
Functional Proteomics Laboratory,, Proteored-ISCIII, CIBERehd, Madrid, Spain.
Methods Mol Biol. 2019;2044:3-23. doi: 10.1007/978-1-4939-9706-0_1.
Brain proteomics has become a method of choice that allows zooming-in where neuropathophysiological alterations are taking place, detecting protein mediators that might eventually be measured in cerebrospinal fluid (CSF) as potential neuropathologically derived biomarkers. Following this hypothesis, mass spectrometry-based neuroproteomics has emerged as a powerful approach to profile neural proteomes derived from brain structures and CSF in order to map the extensive protein catalog of the human brain. This chapter provides a historical perspective on the Human Brain Proteome Project (HBPP), some recommendation to the experimental design in neuroproteomic projects, and a brief description of relevant technological and computational innovations that are emerging in the neurobiology field thanks to the proteomics community. Importantly, this chapter highlights recent discoveries from the biology- and disease-oriented branch of the HBPP (B/D-HBPP) focused on spatiotemporal proteomic characterizations of mouse models of neurodegenerative diseases, elucidation of proteostatic networks in different types of dementia, the characterization of unresolved clinical phenotypes, and the discovery of novel biomarker candidates in CSF.
脑蛋白质组学已成为一种首选方法,它能够深入研究神经病理生理改变发生的部位,检测最终可能在脑脊液(CSF)中作为潜在神经病理学衍生生物标志物进行测量的蛋白质介质。基于这一假设,基于质谱的神经蛋白质组学已成为一种强大的方法,用于分析源自脑结构和CSF的神经蛋白质组,以绘制人类大脑广泛的蛋白质目录。本章提供了关于人类脑蛋白质组计划(HBPP)的历史视角,对神经蛋白质组学项目实验设计的一些建议,以及由于蛋白质组学界而在神经生物学领域出现的相关技术和计算创新的简要描述。重要的是,本章重点介绍了HBPP以生物学和疾病为导向的分支(B/D-HBPP)的最新发现,该分支专注于神经退行性疾病小鼠模型的时空蛋白质组学表征、不同类型痴呆中蛋白质稳态网络的阐明、未解决临床表型的表征以及CSF中新型生物标志物候选物的发现。